An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

Study of Investigational Medication for Ulcerative Colitis (a Digestive Tract Condition)

Recruiting
16 years - 80 years
All
Phase 3
980 participants needed
91 Locations

Study Overview

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis (UC). Study details include:

The study duration may be up to 35 weeks with:

  • Screening period
  • 12-week Sub-Study 1 (Single-Arm Open-Label Feeder Induction) or Sub-Study 2 (Pivotal Induction)
  • 12-week Sub-Study 3 (Extended Induction for non-responders)
  • 45 days follow-up visit for participants who do not enroll into the maintenance study (EFC18359)

The treatment duration will be up to 12 weeks in each sub-study. The number of scheduled on-site visits will be up to 8 for the Sub-Study 1 and Sub Study 2 or a maximum of 15 visits for participants completing extended induction.

Eligibility Criteria

You may be eligible for this study if you meet the following criteria:

  • Conditions: Ulcerative Colitis
  • Age: 16 years - 80 years
  • Gender: All

Inclusion Criteria:

  • Participants aged ≥18 and ≤80 years of age at Screening. Where permitted locally, participants 16 to <18 years of age who meet the definition of Tanner Stage 5 for development
  • Confirmed diagnosis of moderately to severely active UC for at least 3 months prior to Baseline
  • Demonstrated inadequate response, have shown loss of response or intolerance to conventional therapies or advanced therapies

Exclusion Criteria:

  • Participants with Crohn's Disease (CD), indeterminate colitis
  • Current diagnosis of Ulcerative Proctitis
  • Participants with surgical bowel resection within the past 3 months prior to Baseline, or a history of >3 bowel resections
  • Prior or current high-grade gastrointestinal (GI) dysplasia
  • Participants on treatment with but not on stable doses of conventional therapies prior to baseline
  • Participants with prohibited medications or therapies prior to baseline
  • Participants with previous exposure to anti-TL1A investigational therapy The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

This study investigates the effects of an investigational medication on people with moderately to severely active ulcerative colitis.

The study focuses on evaluating the safety and effectiveness of the investigational medication for ulcerative colitis. Researchers aim to understand how well the medication works and how safe it is for participants.

  • Who can participate: Adults aged 18 to 80 years with moderately to severely active ulcerative colitis can participate. Younger participants aged 16 to under 18 years may join if they meet specific development criteria. Participants must have a confirmed diagnosis and have not responded well to previous treatments.
  • Study details: Participants will take part in a study involving on-site visits. The study involves taking an investigational medication to assess its effects on ulcerative colitis.
  • Study timelines and visits: The study will last up to 35 weeks. The study requires up to 15 visits.
Updated on 27 Mar 2026. Study ID: NCT07184996

Find a study site near you

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
United States Only: Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language